About MARA Rating: We provide an independent Market‑Access Risk Assessment (A++ → C) built on a transparent, 10‑domain HTA framework. Use the score to benchmark an asset’s access prospects against
MARA Rating Insight: Why Resource Use & Cost Implications Decide Coverage Since 2020, one pattern has been clear in our database: Assets averaging 2.8 in Resource Use & Cost progressed through HTA
MARA Rating’s Care Pathway Integration score (A++–C) predicts HTA endorsement and payer adoption by measuring clinical guideline alignment, workflow efficiency, administration ease, and implementation feasibility. Too often, M&A teams under-weight
MARA Rating’s Patient Population score (A++–C) predicts HTA approval & reimbursement success. Learn how robust subgroup analysis and real-world evidence drive payer confidence. Too often, M&A teams under-weight market-access risk—patient
Lecanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for early Alzheimer’s disease. The complimentary MARA Rating® report evaluates Lecanemab’s market access prospects for the treatment of
Donanemab — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for Alzheimer’s disease. Donanemab has been evaluated under the MARA Rating framework for its role in slowing cognitive
MARA Rating in the Workflow: How Market Access & BD Teams Use It to Make Better Asset Calls (MARA Rating stands for Market Access Risk Assessment Rating.) Most valuations overweight
Aficamten — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for hypertrophic cardiomyopathy. This complimentary MARA Rating® report evaluates Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
Independent MARA® Ratings quantify HTA reimbursement risk for pharma assets. 5-year 97% precision across 10 domains. Request your report today. MARA Rating Insight Since 2020, assets averaging a 2.9 Comparator Selection score sailed
Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety